Karen Hoelzer

Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer

Gerald Batist, Gopal Ramakrishnan, Chandra Sekhar Rao et al. · Journal of Clinical Oncology · 2001 · 653 citations

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Physical Activity and Health Outcomes Three Months After Completing a Physical Activity Behavior Change Intervention: Persistent and Delayed Effects

Laura Q. Rogers, Patricia Hopkins‐Price, Sandy Vicari et al. · Cancer Epidemiology Biomarkers & Prevention · 2009 · 128 citations · Full text

Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast Cancer

Edgardo Rivera, Vicente Valero, Banu Arun et al. · Journal of Clinical Oncology · 2003 · 89 citations

Biobehavioral Factors Mediate Exercise Effects on Fatigue in Breast Cancer Survivors

Laura Q. Rogers, Sandra Vicari, Rita A Trammell et al. · Medicine & Science in Sports & Exercise · 2013 · 87 citations · Full text